头孢哌酮 / 舒巴坦引起血小板减少症的循证分析

李颖;胡永芳 ;彭芳辰

中国药学杂志 ›› 2009, Vol. 44 ›› Issue (24) : 1938-1941.

PDF(2437 KB)
中国药学杂志
PDF(2437 KB)
中国药学杂志 ›› 2009, Vol. 44 ›› Issue (24) : 1938-1941.
论文

头孢哌酮 / 舒巴坦引起血小板减少症的循证分析

  • 李颖 1,2 ，胡永芳 1* ，彭芳辰 2
作者信息 +

Evidence-Based Analysis of Thrombocytopenia Caused by C efoperazone/Sulbactam

  • LI Ying1,2 ， HU Yong-fang1* ， PENG Fang-chen2
Author information +
文章历史 +

摘要

目的 评价使用头孢哌酮 / 舒巴坦与血小板减少症的相关性。 方法 通过 Cochrane 图书馆， Pubmed ， PDR ， MicroMedex 以及 CNKI ，查阅近年来头孢哌酮 / 舒巴坦与血小板减少症相关的文献，并对我院呼吸重症监护病房 2007 年 9 月 1 日～ 2008 年 9 月 30 日的住院患者进行头孢哌酮 / 舒巴坦使用情况调查。 结果 文献证据和我院临床证据表明，使用头孢哌酮 / 舒巴坦引起血小板减少症的发生率分别约 3.8 ％和 9.68 % 。 结论 使用头孢哌酮 / 舒巴坦可造成血小板减少症。

Abstract

OBJECTIVE To evaluate the relationship between cefoperazone/sulbactam and thrombocytopenia. METHODS ■The relevant literature of Cochrane, Pubmed, PDR, MicroMedex and CNKI in recent years were reviewed. The in-patients treated with cefoperazone/sulbactam in RICU of hospital were involved in the study from Sep.1 2007 to Sep.30 2008. RESULTS ■Literature and clinical evidences showed that the incidence of thrombocytopenia caused by cefoperazone/sulbactam were about 3.8% and 9.68%, respectively. CONCLUSION There is a significant relationship between cefoperazone/sulbactam therapy and thrombocytopenia.

关键词

头孢哌酮 / 舒巴坦 / 血小板减少症 / 相关性

Key words

cefoperazone/sulbactam / thrombocytopenia / association / evidence-based

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
李颖;胡永芳 ;彭芳辰 . 头孢哌酮 / 舒巴坦引起血小板减少症的循证分析[J]. 中国药学杂志, 2009, 44(24): 1938-1941
LI Ying;HU Yong-fng;PENG Fng-chen . Evidence-Based Analysis of Thrombocytopenia Caused by C efoperazone/Sulbactam[J]. Chinese Pharmaceutical Journal, 2009, 44(24): 1938-1941

参考文献


[1] REDDY J, BAILEY R R. Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics [J]. N Z Med J, 1980, 92 (672): 378-379.
[2] BAILEY R R, PEDDIE B, BLAKE E, et al. Cefoperazone in the treatment of severe or complicated infections [J]. Drugs. 1981; 22 Suppl 1: 76-86.
[3] LIPSKY J J. Antibiotic-associated hypoprothrombinaemia [J]. J Antimicr Chemother, 1988, 21 (3): 281-300.
[4] SATTLER F R, WEITEKAMP M R, BALLARD J O, et al. Potential for bleeding with the new beta-lactam antibiotics [J]. Ann Intern Med . 1986, 105 (6): 924-931.
[5] FREEDY H R J R, CETNAROWSKI A B, LUMISH R M, et al. Cefoperazone-induced coagulopathy [J]. Drug Intell Clin Pharm, 1986, 20 (4): 281-283.
[6] ALITALO R, RUUTU M, VALTONEN V, et al. Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone. Report of three cases [J]. Ann Clin Res, 1985, 17 (3): 116-119.
[7] WHITE L O, HOLT A, BYWATER M, et al. Metabolism of beta-lactam antibiotics[J]. N Engl J Med. 1981, 304 (12): 734-735.
[8] KAMMER R B. Cefaclor in management of streptococcal pharyngitis, otitis media, and skin infections [J]. Ann Otol Rhinol Laryngol ( suppl ) , 1981, 90 : 79-81.
[9] HOOPER C A, HANEY B B, STONE H H. Gastrointestinal bleeding due to vitamin K deficiency in patients on parenteral cefamandole [J]. Lancet , 1980, 8158 (1): 39-40.
[10] SUZUKI K, HORIBA M. Laboratory and clinical study of sulbactam/cefoperazone (SBT/CPZ) on bacterial prostatitis [J]. Hinyokika Kiyo, 1991, 37(10): 1333-1343.
[11] KAJIKI A, YAMAZAKI H, HASEGAWA O. Clinical experience with cefoperazone in respiratory tract infections and studies on its penetration into pleural effusion [J]. Jpn J Antibiot, 1983, 36 (12): 3456-3462.
[12] KORNBRUST D, EYDELLOTH R, GARRATTY G. Investigations of the potential for five beta-lactam antibiotics to elicit type II hypersensitivity reactions in rats and monkeys [J]. Fundam Appl Toxicol , 1989, 12 (3): 558-566.
[13] DUAN L F, ZHANG W X. Thrombocytopenia induced by cefoperazone-sulbactam report of 2 cases [J]. Chin J Infect Chemother( 中国感染与化疗杂志 ), 2008, 8 (4): 313.
[14] JIANG W, ZHANG L. Thrombocytopenia due to cefoperzone sodium and sulbactam sodium [J]. Med J Nat Def Forces North China( 华北国防医药 ), 2006, 18 (4): 277.
[15] HU M X. A case of nose bleeding induced by cefoperazone-sulbactam [J]. Pract Pharm Clin Remed ( 实用药物与临床 ), 2008, 11 (3): 151.
[16] LIANG X L, SONG J H, PEI Y F. Thrombocytopenia due to cefoperzone sodium and sulbactam sodium [J]. Adverse Drug React J ( 药物不良反应杂志 ), 2007, 9 (5): 367-368.
[17] ZHAO Q L ， CHEN J K ， WU G Y, et al. Thrombocytopenia due to cefoperzone sodium and sulbactam sodium [J]. J Southeast China Nat Def Med Sci ( 东南国防医学 ), 2006, 8 (4): 318.
[18] XU H, JIANG R M. Acute arrest of hemopoiesis induced by cefoperazone sodium/sulbactam sodium[J]. Adverse Drug React J ( 药物不良反应杂志 ), 2005, 7 (4): 262.
[19] DAI Y. A case of nursing thrombocytopenia patients induced by Hai Shubi [J]. J Nanhua Univ ( Med Ed ) ( 南华大学学报 医学版 ), 2008, 36(5):716-717.
[20] QIN B J. A case of t hrombocytopenia induced by cefoperazone and its mechanism [J]. <>Chin J New Drugs( 中国新药杂志 ) ， 1992, 1 (5): 47-48.
[21] LIU Y J, LIU S W, LI J. 5 Cases of thrombocytopenia induced by cefoperazone [J]. Adverse Drug React J ( 药物不良反应杂志 ), 2002, 7 (1): 44.
[22] DENG Y F, CHEN L F. Analysis of 307 cases of drug-induce thrombocytopenia [J]. Tianjin Pharm.( 天津药学 ), 2007, 19 (1): 33-35.
[23] LV P, LI S Y. Adverse reactions in blood system of cephalosporins and prevention [J]. Med Recapit （医学综述） , 2001, 7 (9): 572-573.
[24] CHEN X Q, JIN Y Y, TANG G. New Materia Medica Pharmacology( 新编药物学 ) [M]. 12nd ed. Beijing: People’s Medical Publishing House , 2007: 57.
[25] LI D K, JIN Y G, TANG G. Martindale : The Complete Drug Reference ( 马丁代尔药物大典 ) [M]. 35th ed. Beijing: Chemical Industry Press, 2009, 197.
（ 收稿日期 ： 2009-08-10 ）


PDF(2437 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉